ICL 749B

Drug Profile

ICL 749B

Alternative Names: Deferoxamine depot; Desferrioxamine depot

Latest Information Update: 23 Mar 2000

Price : $50

At a glance

  • Originator Novartis
  • Class
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Iron overload

Most Recent Events

  • 23 Mar 2000 The results from 3 phase IIa studies have been added to the Haematological Disorders therapeutic trials section
  • 20 Oct 1999 Discontinued-II for Iron overload in United Kingdom (SC)
  • 20 Oct 1999 Discontinued-II for Iron overload in Italy (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top